美因基因(6667.HK)首日上市半日收漲3.33%
格隆匯6月22日丨美因基因(6667.HK)今日首日上市,盤初一度衝高漲超16%報21港元,半日收漲3.33%報18.6港元,成交5971萬港元,最新市值44.5億港元。美因基因是中國最大的消費級基因檢測及癌症篩查基因檢測平台。2019-2021年,公司分別產生總收入人民幣1.24億元、2.03億元及2.37億元。同期錄得淨利潤分別為人民幣0.3億元、0.79億元及0.79億元,以及毛利潤分別為0.78億元、1.46億元及1.67億元人民幣。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.